stockrowPrecigen, Inc.
PGENPrecigen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.7 million, up 146.7% from fiscal 2024.
- Revenue
- +2,437.6%
- EPS
- +109.4%
- Free cash flow
- +138.9%
- Total debt
- +1.47%
Quarter to September 2026, against a year earlier
Follow PGEN
Alert me
Precigen, Inc. (PGEN) Return on invested capital
Precigen, Inc.'s return on invested capital over the twelve months to 30 September 2026 was 15.9%, up 441.6 percentage points from fiscal 2025 (−425.6%). Over the past ten years it has ranged from −425.6% (fiscal 2025) to 0.00% (fiscal 2024) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −425.6% | (425.63) |
| FY2024 | 0.00% | 112.05 |
| FY2023 | −112.1% | (50.73) |
| FY2022 | −61.3% | (29.15) |
| FY2021 | −32.2% | 6.66 |
| FY2020 | −38.8% | 9.73 |
| FY2019 | −48.6% | 14.40 |
| FY2018 | −63.0% | (50.29) |
| FY2017 | −12.7% | 10.82 |
| FY2016 | −23.5% | (4.17) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PGEN Precigen, Inc. | 15.9% |
| NVAX Novavax, Inc. compare | 0.00% |
| NBTX Nanobiotix S.A. - Sponsored ADR compare | 0.00% |
| RARE Ultragenyx Pharmaceutical Inc. compare | 0.00% |
| SLS SELLAS Life Sciences Group, Inc. compare | 0.00% |
| QURE uniQure N.V. compare | 0.00% |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | 0.00% |
| IMCR Immunocore Holdings PLC Sponsored ADR compare | 0.00% |
| NTLA Intellia Therapeutics, Inc. compare | −195.3% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)